Acetylon Pharmaceuticals (United States)

Recent papers from Acetylon Pharmaceuticals (United States)

1. HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe diseaseFrontiers in Molecular Neuroscience · 2023
2. HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease2023
3. Intranasal Use of Prescription Stimulants Among Adults Aged 18 to 30: Results From A Crowdsourcing PlatformJournal of Attention Disorders · 2022
4. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib StudyFrontiers in Oncology · 2021
5. First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory LymphomaThe Oncologist · 2021
6. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristicsJournal for ImmunoTherapy of Cancer · 2019
7. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemiaBlood Advances · 2018
8. NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical ModelCancer Research · 2018
9. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growthNeurobiology of Disease · 2017
10. Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice.2017
11. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patientsNature Communications · 2017
12. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemiaLeukemia · 2017
13. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung CancerCancer Discovery · 2017
14. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitorPLoS ONE · 2017
15. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathyPain · 2017
16. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid LeukemiaPLoS ONE · 2017
17. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple MyelomaClinical Cancer Research · 2017
18. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth DiseaseNeurotherapeutics · 2016
19. Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor modelsOncotarget · 2016
20. Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2PLoS ONE · 2016